PHOENIX, AZ (October 28, 2021) – Renalogic, an industry leader in chronic kidney disease risk management and cost containment, today announced the formation of the company’s Advisory Board. Tasked with helping the company advance its mission to manage the human and financial costs of chronic kidney disease, the Advisory Board includes leading figures from multiple segments of healthcare including employee benefit management, insurance, healthcare providers and academic research.
“When it was founded in 2002, Renalogic was the first company to focus on supporting employers whose employees were affected by chronic kidney diseases,” said Renalogic CEO Kevin Weinstein. “Now, as the company continues to accelerate and break new ground in the fight against kidney disease, we are excited to launch our Advisory Board which will help Renalogic better serve existing and prospective clients, develop new products, and help influence meaningful policy changes.”
Initial members of the Renalogic Advisory Board include (in alphabetical order):
· Jeb Dunkelberger started his career as a healthcare economist and then transitioned to leading innovation initiatives at McKesson and Highmark. Jeb applied his healthcare expertise for smaller companies before taking over as CEO at Sutter Health | Aetna.
· Richard Jones has been a strategic advisor to hundreds of clients in the area of employee benefits for the better part of two decades. Earlier in his career, Richard was a management consultant with Accenture, and was part of the staff that produced the 1996 Olympics in Atlanta.
· Rose Maljanian is currently CEO or HealthCAWS, a privately held health care services company focused on strategic advisory, M&A and platform tools that impact behaviors and outcomes. Earlier in her career Rose held leadership roles with leading provider and payer institutions such as Hartford Hospital, Magellan Health Services, and Humana.
· Ryan McDeviit is an economics professor associated with both Duke University and the University of Chicago. Ryan is the leading academic doing research into the market dynamics of dialysis. His work has been featured in numerous economic journals and publications and has been mentioned in leading popular press outlets such as NPR, The Daily Show, and the LA Times.
“With the additional expertise and insights provided by the advisory board, Renalogic is now even better positioned to support our clients and partners,” Weinstein said.
About Renalogic
Founded in 2002, Renalogic has been the industry leader in dialysis cost containment for nearly 20 years. The company’s predictive analytics identify potential risks associated with kidney disease while its Kidney Dialysis Avoidance Program delivers tailored intervention that slows, stops and in some cases reverses members’ trajectory toward dialysis. For those plan members that do not participate in intervention, or who are already in dialysis, the company’s proprietary claims repricing methodology provides net savings of up to 85%, which can translate to more than $1 million in savings per dialysis patient. In March 2021, Renalogic announced Carrick Capital Partners’ growth recapitalization of the privately held company. For more information, please visit
